The US Food and Drug Administration has approved Crinecerfont for treatment of classic congenital adrenal hyperplasia, ...

"The FDA will continue working with patients, drug companies and health care providers to address the unmet medical needs of the rare disease ... a warning for acute adrenal insufficiency or ...

UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...

Patients with adrenal insufficiency face heightened risks for cardiovascular disease and mortality ... distinctively during periods of acute physiological stress, such as a heart attack. To assess how ...

cSCC remains a disease ... severity. Adrenal insufficiency occurred in 0.9% (2/223) of patients receiving UNLOXCYT, including Grade 2 in 0.4% (1/223) of patients. UNLOXCYT can cause immune-mediated ...

Secondary adrenal insufficiency can also result from long ... The AADAI website lists causes including: If an acute illness, infection, injury or medical procedure or surgery increases the body ...

AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive ...

Ionis Pharmaceuticals is advancing the investigational RNA-targeted therapy olezarsen for the treatment of familial ...

The FDA has approved 43 novel drugs so far this year (January-November), compared to 52 during the same period last year. As we step ...